SCHEMBL20165197

SCHEMBL20165197

CC(C)(C)C(=O)Oc1ccc2c(c1)SCCC=C2OS(=O)(=O)C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ELANE P08246 13/20 0.40
CA2 P00918 5/20 0.36
HSD11B1 P28845 1/20 0.33
KDM4E B2RXH2 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20165337 0.92 ELANE (0.40) ELANECA2HSD11B1
SCHEMBL22664171 0.90 ELANE (0.42) ELANECA2HSD11B1
SCHEMBL29756881 0.83 ELANE (0.40) ELANECA2HSD11B1
SCHEMBL20165338 0.83 ELANE (0.40) ELANECA2HSD11B1
SCHEMBL29756763 0.81 ELANE (0.39) ELANECA2HSD11B1
SCHEMBL19132407 0.81 ELANE (0.39) ELANECA2HSD11B1
SCHEMBL20165456 0.79 ELANE (0.38) ELANECA2HSD11B1
SCHEMBL24362524 0.79 ALDH1A1 (0.40) CA2KDM4E
SCHEMBL19132601 0.78 ELANE (0.38) ELANECA2HSD11B1
SCHEMBL20165031 0.77 ELANE (0.39) ELANECA2HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4508028-B1 NOVEL SUBSTITUTED 4-AMINO-4-OXO-BUT-2-ENYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI SA (FR) 2026-03-11 EP disclosed
US-20250262186-A1 NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE AND N-PROPYL-AZETIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2025-08-21 US disclosed
US-20250248970-A1 NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2025-08-07 US disclosed
US-20250250231-A1 NOVEL SUBSTITUTED 4-AMINO-4-OXO-BUT-2-ENYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT (FR) 2025-08-07 US disclosed
US-20250250261-A1 NOVEL SUBSTITUTED FLUORINATED VINYL-N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2025-08-07 US disclosed
EP-3541809-B1 NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI SA (FR) 2025-06-25 EP disclosed
EP-4508028-A1 NOVEL SUBSTITUTED 4-AMINO-4-OXO-BUT-2-ENYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF Sanofi (FR) 2025-02-19 EP disclosed
EP-4508031-A1 NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF Sanofi (FR) 2025-02-19 EP disclosed
EP-4508033-A1 NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE AND N-PROPYL-AZETIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF Sanofi (FR) 2025-02-19 EP disclosed
EP-4508032-A1 NOVEL SUBSTITUTED FLUORINATED VINYL-N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF Sanofi (FR) 2025-02-19 EP disclosed
WO-2023198879-A1 NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2023-10-19 WO disclosed
WO-2023198905-A1 NOVEL SUBSTITUTED FLUORINATED VINYL-N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2023-10-19 WO disclosed
WO-2023198901-A1 NOVEL SUBSTITUTED 4-AMINO-4-OXO-BUT-2-ENYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2023-10-19 WO disclosed
WO-2023198903-A1 NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE AND N‑PROPYL-AZETIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2023-10-19 WO disclosed
US-20220204488-A1 Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof SANOFI (FR) 2022-06-30 US disclosed
US-20220204488-A1 Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof SANOFI (FR) 2022-06-30 US disclosed
US-11149031-B2 Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof SANOFI (FR) 2021-10-19 US disclosed
US-20200361918-A1 NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR) 2020-11-19 US disclosed
EP-3541809-A1 NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF Sanofi (FR) 2019-09-25 EP disclosed
WO-2018091153-A1 NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361918-A1 NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF ESR1, CYP19A1, ESR2 ELANE 2364/4885CA2 2722/4885HSD11B1 251/4885
US-20250250231-A1 NOVEL SUBSTITUTED 4-AMINO-4-OXO-BUT-2-ENYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF ESR2, ESRRA, CYP19A1 ELANE 877/4885CA2 1432/4885HSD11B1 169/4885
US-11149031-B2 Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof ESR1, CYP19A1, ESR2 ELANE 2492/4885CA2 2439/4885HSD11B1 275/4885
US-20220204488-A1 Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof ESR1, CYP19A1, GPER1 ELANE 2242/4885CA2 2189/4885HSD11B1 161/4885
US-20250250261-A1 NOVEL SUBSTITUTED FLUORINATED VINYL-N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF FSHR, GPER1, ESRRA ELANE 1814/4885CA2 1498/4885HSD11B1 458/4885
US-20250262186-A1 NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE AND N-PROPYL-AZETIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF FSHR, CYP19A1, GPER1 ELANE 1718/4885CA2 1575/4885HSD11B1 862/4885
US-20250248970-A1 NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF FSHR, ESRRA, GPER1 ELANE 1314/4885CA2 1603/4885HSD11B1 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.